Cargando…

Renin-Angiotensin-Aldosterone System Blockers Are Not Associated With Coronavirus Disease 2019 (COVID-19) Hospitalization: Study of 1,439 UK Biobank Cases

Background: Cardiometabolic morbidity and medications, specifically Angiotensin Converting Enzyme inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs), have been linked with adverse outcomes from coronavirus disease 2019 (COVID-19). This study aims to investigate, factors associated with COVID...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raisi-Estabragh, Zahra, McCracken, Celeste, Ardissino, Maddalena, Bethell, Mae S., Cooper, Jackie, Cooper, Cyrus, Harvey, Nicholas C., Petersen, Steffen E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381180/ https://www.ncbi.nlm.nih.gov/pubmed/32766285 http://dx.doi.org/10.3389/fcvm.2020.00138

Ejemplares similares

Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2020)

Pericardial adiposity is independently linked to adverse cardiovascular phenotypes: a CMR study of 42 598 UK Biobank participants( )
por: Ardissino, Maddalena, et al.
Publicado: (2022)

Associations of Meat and Fish Consumption With Conventional and Radiomics Cardiovascular Magnetic Resonance Phenotypes in the UK Biobank
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2021)

Lower birth weight is linked to poorer cardiovascular health in middle-aged population-based adults
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2023)

Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2023)

Associations of cognitive performance with cardiovascular magnetic resonance phenotypes in the UK Biobank
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2021)

Neuroticism personality traits are linked to adverse cardiovascular phenotypes in the UK Biobank
por: Mahmood, Adil, et al.
Publicado: (2023)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Age, sex and disease-specific associations between resting heart rate and cardiovascular mortality in the UK BIOBANK
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2020)

The Impact of Maternal Obesity on Offspring Cardiovascular Health: A Systematic Literature Review
por: Kankowski, Lois, et al.
Publicado: (2022)

Multi-organ imaging demonstrates the heart-brain-liver axis in UK Biobank participants
por: McCracken, Celeste, et al.
Publicado: (2022)

Adverse cardiovascular magnetic resonance phenotypes are associated with greater likelihood of incident coronavirus disease 2019: findings from the UK Biobank
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2021)

Incident Clinical and Mortality Associations of Myocardial Native T1 in the UK Biobank
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2023)

Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis
por: Morishita, Yoshiyuki, et al.
Publicado: (2014)

Meta-analysis of effect of renin–angiotensin–aldosterone system blockers on contrast-induced nephropathy
por: Wang, Weidong, et al.
Publicado: (2020)

Characterizing the hypertensive cardiovascular phenotype in the UK Biobank
por: Elghazaly, Hussein, et al.
Publicado: (2023)

Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2023)

The role of obesity-related cardiovascular remodelling in mediating incident cardiovascular outcomes: a population-based observational study
por: Szabo, Liliana, et al.
Publicado: (2023)

Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?
por: Copur, Sidar, et al.
Publicado: (2022)

Assessment of Oxidative Stress Markers in Hypertensive Patients under the Use of Renin-Angiotensin-Aldosterone Blockers
por: Vazquez-Agra, Nestor, et al.
Publicado: (2023)

Left atrial structure and function are associated with cardiovascular outcomes independent of left ventricular measures: a UK Biobank CMR study( )
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2021)

Corrigendum to: Left atrial structure and function are associated with cardiovascular outcomes independent of left ventricular measures: a UK Biobank CMR study
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2022)

Renin-angiotensin-aldosterone system blockers in Bulgarian COVID-19 patients with or without chronic kidney disease
por: Filev, Rumen, et al.
Publicado: (2022)

An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers
por: Maideen, Naina Mohamed Pakkir, et al.
Publicado: (2022)

Addition of a renin-angiotensin-aldosterone system inhibitor to a calcium channel blocker ameliorates arterial stiffness
por: Kiuchi, Shunsuke, et al.
Publicado: (2015)

Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation
por: Rodriguez-Padial, Luis, et al.
Publicado: (2017)

Vitamin D supplementation and COVID-19 disease: safety but unproven efficacy—reply to Dr Helga Rhein
por: Harvey, Nicholas C., et al.
Publicado: (2021)

Vitamin D and COVID-19 disease: don’t believe everything you read in the papers! Reply to Dr William B. Grant
por: Harvey, Nicholas C., et al.
Publicado: (2021)

Emergence and evolution of the renin–angiotensin–aldosterone system
por: Fournier, David, et al.
Publicado: (2012)

Beyond the Circulating Renin–Angiotensin Aldosterone System
por: De Mello, Walmor C.
Publicado: (2014)

The renin‐angiotensin‐aldosterone system and its suppression
por: Ames, Marisa K., et al.
Publicado: (2019)

The renin angiotensin aldosterone system and COVID-19
por: Alsufyani, Hadeel A., et al.
Publicado: (2020)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Renin-Angiotensin-Aldosterone System Blockers Prior to Hospitalization and Their Association With Clinical Outcomes in Coronavirus Disease 2019 (COVID-19)
por: Banwait, Ranjit, et al.
Publicado: (2021)

Quantitative Value of Aldosterone‐Renin Ratio for Detection of Aldosterone‐Producing Adenoma: The Aldosterone‐Renin Ratio for Primary Aldosteronism (AQUARR) Study
por: Maiolino, Giuseppe, et al.
Publicado: (2017)

Automated Quality-Controlled Cardiovascular Magnetic Resonance Pericardial Fat Quantification Using a Convolutional Neural Network in the UK Biobank
por: Bard, Andrew, et al.
Publicado: (2021)

Active renin mass concentration to determine aldosterone-to-renin ratio in screening for primary aldosteronism
por: Corbin, François, et al.
Publicado: (2011)

Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin–Angiotensin–Aldosterone System Blockers
por: Ueda, Yuichiro, et al.
Publicado: (2016)

Increasing prescription of renin–angiotensin–aldosterone system blockers associated with improved kidney prognosis in Korean IgA nephropathy patients
por: Park, Sehoon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8tjpbj59tpajctbnijcudiu68i